Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 15,54 € (+64,10%). La mediana è 12,52 € (+32,21%).
| Acquista |
4 |
| Mantieni |
8 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Eli Lilly reports positive phase 3 trial results with Pirtobrutinib in CLL
Eli Lilly announced that Pirtobrutinib met the primary endpoint and demonstrated a favorable safety profile in a head-to-head phase 3 trial for chronic lymphocytic leukemia (CLL). The company plans to use these results as the basis for global regulatory submissions and also reported regulatory progress for its Alzheimer’s drug Kisunla, as well as the completion of the acquisition of Verve Therapeutics. Analysts remain positive on Eli Lilly, highlighting its strong financial performance. » Altro su de.investing.com
Verve Therapeutics strengthens leadership team with retention bonuses ahead of planned Eli Lilly acquisition
Verve Therapeutics has introduced a retention bonus program for key personnel to secure management ahead of the planned acquisition by Eli Lilly. CFO Allison Dorval and COO Andrew Ashe will receive bonuses contingent on their remaining with the company until the 12th anniversary following the completion of the acquisition. The acquisition agreement offers Verve shareholders $10.50 per share as well as potential additional benefits, while analysts have mixed views on the development. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | mar 2025 | |
|---|---|---|
| Ricavi | 30,48 Mln | - |
| Utile lordo | 30,48 Mln | - |
| Utile netto | -28,69 Mln | - |
| EBITDA | -32,28 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 858,31 Mln € |
Numero di azioni | 89,31 Mln |
Massimo/minimo a 52 settimane | 9,85 € - 2,47 € |
| Dividendi | No |
Beta | 2,24 |
Rapporto P/E | -4,72 |
Rapporto PEG | -0,14 |
Rapporto P/B | 1,91 |
Rapporto P/S | 30,74 |
Profilo aziendale
Verve Therapeutics, Inc. ist ein Unternehmen für genetische Arzneimittel, das sich mit der Entwicklung von Gen-Editing-Medikamenten für Patienten zur Behandlung von Herz-Kreislauf-Erkrankungen befasst. Der führende Produktkandidat ist VERVE-101, eine einmalige Gene-Editing-Behandlung, die das PCSK9-Gen in der Leber dauerhaft ausschaltet. Das Unternehmen entwickelt auch das ANGPTL3-Programm zur dauerhaften Ausschaltung des ANGPTL3-Gens in der Leber. Es hat eine Kooperations- und Lizenzvereinbarung mit Beam Therapeutics Inc. abgeschlossen, eine Entwicklungs- und Optionsvereinbarung mit Acuitas Therapeutics, Inc. und eine Cas9-Lizenzvereinbarung mit dem Broad Institute und dem President and Fellows of Harvard College. Das Unternehmen war früher als Endcadia, Inc. bekannt und änderte im Januar 2019 seinen Namen in Verve Therapeutics, Inc. Verve Therapeutics, Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.
| Nome | VERVE THERAPEUTICS -,001 |
| CEO | Sekar Kathiresan |
| Sede centrale | Boston,
ma Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 17/06/2021 |
| Dipendenti | 274 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | VERV |
Scopri gli asset
Gli azionisti di VERVE THERAPEUTICS -,001 investono anche nei seguenti asset
